The WHO (World Health Organization) has now recommended the use of the first-ever Malaria Vaccine, RTS, S, also known as Mosquirix. The Organization says it should be deployed for children in sub-Saharan Africa and other areas where malaria transmission is moderate to high. The announcement is the footsteps of huge vaccine advancements around the COVID-19 pandemic. It is noteworthy that RTS, S isn’t an mRNA vaccine, which has the potential to make an even bigger impact on malaria and other diseases that have affected humans for ages. The WHO Director-General Dr. Tedros Adhanom Ghebreyesus issued a statement and said, “This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health, and malaria control Read more....
The only currently approved malaria vaccine as of today is RTS, R, formulated by the same brand name Mosquirax.
It usually takes four injections, has low efficiency, and takes about six weeks for it to become complete.
The advantages of these malaria vaccines are manifold.
In clinical trials, volunteers who were given the placebo showed higher efficacy against flaviviruses than those who were administered the real thing.
Likewise, the efficacy of the real thing was found to be similar to that of the placebo.Malaria Vaccines are given individually or in combination with other malaria vaccines.
This can be done by taking vitamin supplements, which are known to boost immunity.
Summary Action Potential Venture Capital is the bioelectronic medicines venture arm of GSK.
It is focused on investing in start-ups which are involved in development of neuromodulation medical devices and adaptive bioelectronics.
Headquartered in Palo Alto, the venture arm invests in start-ups across the globe.
The report provides information and insights into GSK's tech activities, including -- Insights of its digital transformation strategies and venture arm- Overview of technology initiatives covering partnerships and technology launches- Insights on each technology initiative including technology theme, objective, and benefits- Details of estimated ICT budgets and major ICT contracts.Scope - GlaxoSmithKline is tapping key disruptive technologies to strengthen its operational and service competences.
Artificial Intelligence, IoT, Big Data, Blockchain, Mobile Health, Robotics, and Augmented Reality are the key technologies under focus for the company.
Cloud, Genomic, and Ecommerce are the other focusing areas of the company.- GlaxoSmithKline plc is investing in emerging technologies and is also building an internal team with data, analytics and insights, content, media, and e-commerce experts to win the digital competition.- Using AI and machine learning (ML) for Drug Discovery & Development- Focus on Functional GenomicsReasons to Buy - Gain insights into GSK's tech operations.- Gain insights into its tech strategies and innovation initiatives.- Gain insights into its technology themes under focus.- Gain insights into various product launches and partnerships strategies of GSKGet the Complete Report & TOC @ https://www.primemarketreports.com/reports/2494/glaxosmithkline-plc-enterprise-tech-ecosystem-series-520Table of contentTable of ContentsOverviewDigital Transformation StrategyDisruptive Tech Theme MapTechnology InitiativesKey ExecutivesVenture Arm-SR OneSR One InvestmentsAction Potential Venture Capital (APVC) Venture ArmICT Budget & ContractsInvestor - Partner Network MapDisclaimerCONTACT US:North Main Road Koregaon Park, Pune, India - 411001.International: +1(646)-781-7170Asia: +91 9169162030Email: help@primemarketreports.com
According to WHO, India made strong progress in the fight against malaria, recording the largest reduction in cases in South-East Asia from 20 million in 2000 to about 5.6 million last year.
